Company profile
iAnthus Capital Holdings, Inc.
OTC: ITHUF · Healthcare · Drug Manufacturers - Specialty & Generic
PublicHQ Toronto, NYCIK 0001643154Reports USD
#315 of 1,418 Healthcare companies by revenue30th-percentile growth
EA Score
46DFH 48DQ 40GM 47SS 60
v0.1 · 65/100 weight · provisional
↑ workforce scale, growth stability · ↓ Piotroski F, balance-sheet leverage
Methodology →Revenue TTM
$139.9M
Rev growth YoY (TTM)
-14.3%
Net income (FY)
-$40.2M
Employees
792
as of 2026-08-20
Market cap
$27.9M
as of 2026-08-20
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$144.0M$144.0M2025
Net income-$40.2M-$40.2M2025
Operating income-$15.4M-$15.4M2025
Total assets$256.0M$256.0M2025
Liabilities$359.0M$359.0M2025
Equity-$103.0M-$103.0M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
iAnthus Branded Products44%
Third Party Branded Products38%
Wholesale Bulk Other Products18%
By geography
Eastern Region93%
Western Region7%
The read
What is iAnthus Capital Holdings, Inc.’s revenue?
iAnthus Capital Holdings, Inc. booked $144.0M in FY2025 revenue, contracting 14% year over year — slower than 70% of Healthcare companies we track, at a -27.9% net margin.
Peers · Healthcare
GRAIL Inc.51DCronos Group Inc.69BKaryopharm Therapeutics Inc.49DInfuSystem Holdings, Inc.80B+Beam Therapeutics Inc.62CSpok Holdings, Inc.83B+Key facts
CEORichard Proud
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersToronto, NY
ExchangeOTC: ITHUF
Employees792
IPO date2018-03-02
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.